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induced tubulointerstitial lesions in children with MCNS whoRisk factors for cyclosporine-induced tubulointerstitial lesions
had been treated with long-term moderate-dose CsA.in children with minimal change nephrotic syndrome.
Background. Cyclosporine (CsA) is effective for the treat-
ment of children with steroid-dependent and -resistant ne-
phrotic syndrome (NS), but it can result in chronic CsA nephro- The administration of cyclosporine (CsA) is effectivetoxicity including CsA-induced tubulointerstitial lesions. The
for the treatment of children with steroid-dependent andfactors responsible for the development of CsA-induced tubu-
steroid-resistant nephrotic syndrome (NS) [1–5]. Thelointerstitial lesions are unknown.
Methods. To identify the risk factors for the development of beneficial effects of CsA are often accompanied by
CsA-induced tubulointerstitial lesions in children with minimal chronic CsA nephrotoxicity, characterized by arteriolar
change NS who had been treated with long-term moderate- lesions [CsA-associated arteriolopathy (CAA)], and tu-
dose CsA, we compared several clinical and laboratory factors
bulointerstitial lesions [6]. In our previous studies, aof 37 patients with and without CsA-induced tubulointerstitial
moderate-dose CsA treatment for approximately twolesions by the Mann-Whitney U test, Fisher’s exact test, and
stepwise logistic-regression analysis. years in children with steroid-dependent NS was found
Results. Thirteen patients had CsA-induced tubulointersti- to be effective for preventing relapses and decreasing
tial lesions and 24 patients had none. Among clinical and labo- steroid toxicity. However, repeat renal biopsies carried
ratory factors, the duration of CsA treatment (P  0.003) and
out at the end of CsA treatment showed chronic CsAthe duration of heavy proteinuria during CsA treatment (P 
nephrotoxicity in half of these patients [7, 8]. We also0.024) were related to the development of CsA-induced tubulo-
found that in children with idiopathic NS, CAA wasinterstitial lesions as determined by the univariate analyses.
Indeed, CsA-induced tubulointerstitial lesions were found in improved by discontinuation of CsA, but tubulointersti-
2 of 18 (11%) patients who had been treated with CsA for less tial lesions did not regress with drug discontinuation
than 24 months, but in 11 of 19 patients (58%) who had been [9, 10]. Thus, prevention of the development of CsA-treated for more than 24 months (P  0.005). They were also
induced tubulointerstitial lesions is the most importantfound in 4 of 23 patients (17%) who had heavy proteinuria
issue in CsA treatment for children with idiopathic NS.for less than 30 days during CsA treatment, but in 9 of 14
patients (64%) who had heavy proteinuria for more than 30 The factors responsible for the development of CsA-
days (P 0.006). Stepwise logistic-regression analysis revealed induced tubulointerstitial lesions remain unknown. We
that the duration of CsA treatment for more than 24 months therefore examined the risk factors for the development
(2  6.203, P  0.013) and the duration of heavy proteinuria
of CsA-induced tubulointerstitial lesions in 37 childrenduring CsA treatment for more than 30 days (2  5.871, P 
with minimal change NS (MCNS) who had been treated0.015) were independent risk factors for the development of
CsA-induced tubulointerstitial lesions. with long-term moderate-dose CsA.
Conclusions. Duration of the CsA treatment and the dura-
tion of heavy proteinuria during CsA treatment were inde-
pendent significant risk factors for the development of CsA- METHODS
The study was performed at Kobe University Hospital.
All patients or their parents gave their informed consent.Key words: renal lesions, proteinuria, steroid-dependent nephrotic syn-
drome, nephrotoxicity, duration of CsA therapy, arteriolar lesions,
Patientsidiopathic nephrotic syndrome.
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steroid-dependent frequently relapsing NS and 9 had Cyclosporine A-associated arteriolopathy was defined
as arteriolar lesions showing hyalinosis. At least five arte-steroid-resistant NS. CsA treatment led all the latter
patients into complete remission within three months rioles were examined in each specimen. Hyalinosis was
identified as lumpy PAS-positive protein deposits withinafter the start of treatment. Pre-CsA biopsies showed
MCNS in 29 patients, focal segmental glomerulosclerosis or on the outer aspects of the arteriolar walls.
in 3, and diffuse mesangial proliferation in 3. Renal
Statistical analysisbiopsy was not performed in 2 patients before CsA treat-
ment. All pre-CsA biopsies showed no or negligible tu- The values are expressed as mean SE. For univariate
analyses, we used the Mann-Whitney U test to comparebulointerstitial lesions while all post-CsA biopsies showed
MCNS. The mean age at the onset of NS was 5.2  0.6 unpaired two-group means. The Fisher’s exact test was
used to evaluate the association between categorical vari-years (range 1 to 13). The mean age at the start of CsA
therapy was 7.9  0.8 years (range 2 to 16). ables. For multivariate analyses, the forward, stepwise
logistic-regression model was used to identify the riskThe definitions and criteria for NS, remission, relapse,
steroid-dependency, and steroid-resistance were those factors. The differences were evaluated using Stat-View
J-5.0 software (Abacus Concepts Inc., Berkeley, CA,used by the International Study of Kidney Disease in
Children [11, 12]. Heavy proteinuria was defined as 2 USA), and those with P  0.05 were considered signifi-
cant.or more by Albustix in morning spot urine.
CsA treatment
RESULTS
In patients with steroid-dependent NS, after they had
Thirteen post-CsA biopsy specimens showed charac-attained remission with prednisolone therapy, CsA (San-
teristic striped interstitial fibrosis, and they were thusdimmune oral solution, CyA; Novartis Pharma K.K.,
diagnosed as having CsA-induced tubulointerstitial le-Tokyo, Japan) treatment was started at a dose of 100 to
sions. In contrast, 24 post-CsA specimens did not show150 mg/m2 per day (3 mg/kg body weight) in two di-
the lesions.vided doses. In patients with steroid-resistant NS, CsA
To identify the risk factors for the development oftreatment was used to achieve remission. The dose of
CsA-induced tubulointerstitial lesions, the following clini-CsA was adjusted to a target blood trough level of 100
cal and laboratory data were examined: sex ratio, initialng/mL, as measured by monoclonal antibody fluores-
steroid responsiveness, initial biopsy findings, age at on-cence polarization immunoassay. CsA was administered
set of NS, duration between the onset and the start offor at least 18 months. No medicine that might have
CsA treatment, age at the start of CsA treatment, agecontributed to CsA nephrotoxicity was given during the
at the post-CsA biopsy, cyclophosphamide treatment be-CsA treatment period.
fore CsA, duration of CsA treatment, number of NS
Steroid therapy for relapses of NS relapses during CsA treatment per year, duration of
heavy proteinuria during CsA treatment, serum creati-For steroid therapy, only prednisolone was used. Re-
nine at the start and the end of CsA treatment, urinarylapses of NS during CsA treatment and after CsA discon-
2-microglobulin at the start and the end of CsA treat-tinuation were treated with 2 mg/kg per day prednisolone
ment, maximum increase of serum creatinine during CsAgiven in three divided doses (maximum dose 80 mg) for
treatment, mean CsA trough level, and mean blood pres-the first four weeks. This was followed by alternate-day
sure during CsA treatment (Table 1).prednisolone at 2 mg/kg, given as a single dose in the
Among those criteria, both the duration of CsA treat-morning of every other day for two weeks, after which
ment (37.9  5.1 vs. 26.1  1.7 months, P  0.003) andthe dose was decreased by 0.5 mg/kg every two weeks
the duration of heavy proteinuria during CsA treatment(for a total of 12 weeks).
(59.0  13.7 vs. 25.7  9.5 days, P  0.024) were related
Histological evaluation to the development of CsA-induced tubulointerstitial
lesions by the univariate analysis. Indeed, CsA-inducedFor each case, two to four serial sections were pre-
tubulointerstitial lesions were found in 2 of 18 (11%)pared by staining with periodic acid-Schiff (PAS) and
patients who had been treated with CsA for less thanMasson’s trichrome. An investigator who was blinded
24 months, but in 11 of 19 patients (58%) who had beento treatment status reviewed the renal biopsy specimens.
treated for more than 24 months (P 0.005). They wereThe histological diagnosis of idiopathic NS was based
also found in 4 of 23 patients (17%) who had heavyon the criteria of the International Study of Kidney Dis-
proteinuria during CsA treatment for less than 30 days,ease in Children [11, 13]. CsA-induced tubulointerstitial
but in 9 of 14 patients (64%) who had heavy proteinurialesions were defined as characteristic striped tubulointer-
for more than 30 days (P  0.006). The rate of CsA-stitial lesions (tubular atrophy accompanying interstitial
fibrosis) [14]. induced tubulointerstitial lesions increased as the dura-
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Table 1. Clinical and laboratory data and cyclosporine (CsA)-induced tubulointerstitial lesions
CyA-induced tubulointerstitial lesions
Clinical or laboratory data Positive (N  13) Negative (N  24) P-value
Male/female 11/2 18/6 0.685
Initial steroid response dependent/resistant 8/5 20/4 0.229
Initial biopsy findings MCNS/othersa 8/4 21/2 0.151
Age at the onset of disease years 4.80.9 5.40.8 0.633
Duration between the onset and start of CsA treatment years 2.41.0 2.10.4 0.483
Age at the start of CsA treatment years 8.31.4 7.70.9 0.787
Age at the post-CsA biopsy years 11.31.4 9.80.9 0.340
Cyclophosphamide treatment before CsA yes/no 9/4 16/8 0.999
Duration of CsA treatment months 37.95.1 26.11.7 0.003
Duration of CsA treatment 24 months yes/no 11/2 8/16 0.005
N of NS relapses during CsA treatment per year 0.950.23 0.610.17 0.147
Duration of heavy proteinuria during CsA treatment days 59.013.7 25.79.5 0.024
Duration of heavy proteinuria during CsA treatment 30 days yes/no 9/4 5/19 0.006
Serum creatinine at the start of CsA mg/dL 0.390.05 0.420.03 0.550
Serum creatinine at the end of CsA mg/dL 0.510.06 0.460.03 0.533
Maximum increase of serum creatinine % 35.87.7 22.25.2 0.114
Urinary 2-microglobulin at the start of CsA lg/L 13615 14828 0.758
Urinary 2-microglobulin at the end of CsA lg/L 10024 14423 0.233
Mean CsA trough level ng/mL 11012 9511 0.192
Mean blood pressure mm Hg 834 772 0.551
Abbreviations are: MCNS, mininal change nephrotic syndrome; NS, nephrotic syndrome.
a Renal biopsy was not performed in 2 patients before CyA treatment
Table 3. CsA-induced tubulointerstitial lesions and duration ofTable 2. CsA-induced tubulointerstitial lesions
and duration of CsA treatment heavy proteinuria during CsA treatment
CsA-induced tubulointerstitialCsA-induced tubulointerstitial lesions
lesions
Duration of heavy proteinuriaDuration of CsA treatment Positive Negative Positive rate
during CsA treatment Positive Negative Positive rate
24 months 11 8 58%
36 months 5 3 63% 30 days 9 5 64%
60 days 6 3 67%48 months 4 1 80%
90 days 4 1 80%
tion of CsA treatment increased (Table 2). Also, the rate
DISCUSSIONof CsA-induced tubulointerstitial lesions increased as
Cyclosporine A is a useful new agent for the manage-the duration of heavy proteinuria during CsA treatment
ment of steroid-dependent NS in children that replacesincreased (Table 3).
corticosteroids and alkylating agents. It may be of partic-Although 10 post-CsA biopsy specimens showed mild
ular help for patients who experience serious side effectsto moderate CAA, the existence of CAA did not corre-
as a result of continuous steroid therapy. CsA is alsolate with the development of CsA-induced tubulointer-
effective for the treatment of steroid-resistant NS. As
stitial lesions (P  0.118).
discontinuation of CsA treatment often induces frequent
The forward, stepwise logistic-regression analysis re- relapses, a longer period of CsA administration is neces-
vealed that the duration of CsA treatment for more than sary to maintain a long-term remission. However, long-
24 months (2  6.203, P  0.013) and the duration of term CsA treatment often results in chronic CsA nephro-
heavy proteinuria for more than 30 days during CsA toxicity, characterized by CAA and tubulointerstitial le-
treatment (2  5.871, P  0.015) were the independent sions, namely striped fibrosis [7, 8]. In our recent studies,
and significant risk factors for the development of CsA- CAA was improved by discontinuation of CsA, but tubu-
induced tubulointerstitial lesions (Table 4). Neither the lointerstitial lesions did not regress with drug discontinu-
duration of CsA treatment for more than 24 months (2 ation in children with idiopathic NS [9, 10]. Therefore,
3.580, P  0.059) nor the duration of heavy proteinuria it is important to clarify the risk factors for the develop-
during CsA treatment for more than 30 days (2  0.282, ment of CsA-induced tubulointerstitial lesions in order
P  0.595) was the risk factor for the development of to prevent it.
Our current study shows that the duration of CsACAA by the logistic-regression analysis.
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Table 4. Logistic regression analysis for risk factors for CsA-induced tubulointerstitial lesions
Lower 95% Upper 95%
Variable Relative risk confidence limit confidence limit P value
Duration of CsA treatment 24 months 12.39 1.709 89.77 0.013
Duration of heavy proteinuria
during CsA treatment 30 days 9.69 1.543 60.81 0.015
treatment and the duration of heavy proteinuria during 24 months. If patients relapse, they are treated with ste-
roids for 6 to 12 months, then again with CsA for 1 toCsA treatment are risk factors for the development of
CsA-induced tubulointerstitial lesions in children with 2 years, to minimize the toxicity of prolonged administra-
tion of CsA [17]. It is notable that in our study the rate ofMCNS who had been treated with long-term moderate-
dose CsA. The rate of CsA-induced tubulointerstitial CsA-induced tubulointerstitial lesions was significantly
higher in patients who had been treated with CsA forlesions increased as the duration of CsA treatment in-
creased and the rate of CsA-induced tubulointerstitial more than 24 months than in patients who had been
treated with CsA for less than 24 months (58% vs. 11%,lesions increased as the duration of heavy proteinuria
during CsA treatment increased, supporting our conclu- P  0.005). Moreover, the forward, stepwise logistic-
regression analysis revealed that the duration of CsAsions that the two risk factors are related to the develop-
ment of CsA-induced tubulointerstitial lesions. How- treatment for more than 24 months was a significant risk
factor for the development of CsA-induced tubulointer-ever, previous studies have reported that the incidence
of chronic CsA nephrotoxicity including CsA-induced stitial lesions (2 6.203, P 0.013). These data strongly
support Ponticelli and Passerini’s treatment strategy fortubulointerstitial lesions was not related to the duration
of treatment [14–16]. patients with steroid-dependent NS.
The present study also demonstrates that long-termFeutren and Mihatch analyzed data from renal biop-
sies from 192 patients (129 adults and 63 children) who heavy proteinuria during CsA treatment is a significant
risk factor for the development of CsA-induced tubulo-had been treated with CsA for insulin-dependent diabe-
tes mellitus, uveitis, psoriasis, Sjo¨gren’s syndrome, or interstitial lesions. The longer periods of heavy pro-
teinuria during CsA treatment were due mostly to ster-polychondritis. They found that a larger initial dose of
CsA, a larger maximal increase in serum creatinine, and oid-resistant NS or to frequent relapses in spite of CsA
treatment, although neither the steroid resistance norolder age were the risk factors for the development of
chronic CsA nephrotoxicity [14]. However, the mean the number of relapses was the significant risk factor
for the development of CsA-induced tubulointerstitialinitial dose of CsA in their study (8.2 mg/kg body wt/
day) was much higher than that in our study (3 mg/kg lesions. The long-term heavy proteinuria per se might
have induced the development of CsA-induced tubuloin-body wt/day). The mean duration of CsA treatment in
their study (17.7 months) was much shorter than that in terstitial lesions. However, the results of our previous
study regarding the histological changes after CsA dis-our study (30.3 months). Therefore, their study might
have overlooked the significance of the duration of CsA continuation showed that the tubulointerstitial lesions
did not deteriorate after CsA discontinuation althoughtreatment as a risk factor for the development of CsA-
induced tubulointerstitial lesions. Alternatively, the dif- long-term proteinuria due to frequent relapses had been
present over the period between CsA discontinuationference in diseases between their study and our study
may account for the discrepancy. and the repeat renal biopsies [10]. Moreover, it has been
reported in rats that long-term (6 months) massive pro-Habib and Niaudet reported that there was no correla-
tion between chronic CsA nephropathy and the duration teinuria induced by multiple injections of anti-rat slit
diaphragm monoclonal antibody results in tubular epi-of CsA treatment in children with idiopathic nephrotic
syndrome [15, 16]. However, they also found that CsA- thelial cell injury and cell infiltration but not interstitial
fibrosis [18]. Collectively, these findings suggest that CsAinduced tubulointerstitial lesions progressed with time
in patients who underwent serial post-treatment renal and long-term proteinuria can synergistically induce tu-
bulointerstitial lesions by means of unknown mecha-biopsies [16], which suggests that our data are consistent
with theirs. Alternatively, the discrepancy between their nism(s).
It is of note that the existence of CAA is not a signifi-results and ours may be explained by the fact that the
target blood trough level in their study (100 to 200 ng/ cant risk factor for the development of CsA-induced
tubulointerstitial lesions. Neither the duration of CsAmL) was higher than that in ours (100 ng/mL).
Ponticelli and Passerini reported that, in patients with treatment for more than 24 months (2  3.580, P 
0.059) nor the duration of heavy proteinuria during CsAsteroid-dependent NS, CsA should be discontinued after
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was small and it will decrease under 0.05 if the number
of patients increases. However, the P value for the dura-
REFERENCEStion of heavy proteinuria was far from the level of sig-
1. Capodicasa G, De Santo NG, Nuzzi F, Giordano C: Cyclosporinnificance. We recently demonstrated that enhanced im-
A in nephrotic syndrome of childhood—A 14 month experience.munoreactivity to renin was significantly correlated with
Int J Pediatr Nephrol 7:69–72, 1986the development of CAA, but not with the development
2. Niaudet P, Tete MJ, Broyer M, Habib R: Cyclosporin and child-
of tubulointerstitial lesions in CsA-treated idiopathic NS hood idiopathic nephrosis. Transplant Proc 20:265–268, 1988
patients. These findings suggest that activation of the 3. Tejani A, Butt K, Trachtman H, et al: Cyclosporin A induced
remission of relapsing nephrotic syndrome in children. Kidney Intintrarenal renin-angiotensin system is responsible for the
33:729–734, 1988development of CAA, and that the development of CsA-
4. Neuhaus TJ, Burger HR, Klingler M, et al: Long-term low-induced tubulointerstitial lesions is, at least in part, inde-
dose cyclosporin A in steroid-dependent nephrotic syndrome of
pendent of intrarenal renin-angiotensin system activa- childhood. Eur J Pediatr 151:775–778, 1992
tion [9]. The data in the present study provide theoretical 5. Gregory MJ, Smoyer WE, Sedman A, et al: Long-term cyclosporin
therapy for pediatric nephrotic syndrome: A clinical and histologicsupport for the conclusion in our previous study.
analysis. J Am Soc Nephrol 7:543–549, 1996In conclusion, the duration of CsA treatment and the
6. D’agati VD: Morphologic features of cyclosporin nephrotoxicity.duration of heavy proteinuria during CsA treatment Contrib Nephrol 114:84–110, 1995
were independent significant risk factors for the develop- 7. Inoue Y, Iijima K, Nakamura H, Yoshikawa N: Two-year cyclo-
sporin treatment in children with steroid-dependent nephrotic syn-ment of CsA-induced tubulointerstitial lesions in chil-
drome. Pediatr Nephrol 13:33–38, 1999dren with MCNS who had been treated with long-term
8. Yoshikawa N, Iijima K, Ito H: Cyclosporin (cyclosporine) treat-moderate-dose CsA. We recommend that moderate-
ment in children with steroid-dependent nephrotic syndrome. Clin
dose CsA treatment in children with MCNS should be Exp Nephrol 3(Suppl):S27–S33, 1999
limited to less than 24 months, because when it is contin- 9. Iijima K, Hamahira K, Kobayashi A, et al: Immunohistochemical
analysis of renin activity in chronic cyclosporine nephropathy inued for more than 24 months there is a high incidence
childhood nephrotic syndrome. J Am Soc Nephrol 11:2265–2271,of CsA-induced tubulointerstitial lesions. Alternatively,
2000CsA treatment can be continued after the observation
10. Hamahira K, Iijima K, Tanaka R, et al: Recovery from cyclospo-
of minimal histological nephrotoxicity at the end of a rine associated arteriolopathy in childhood nephrotic syndrome.
two-year treatment, although careful subsequent histo- Pediatr Nephrol 16:723–727, 2001
11. International Study of Kidney Disease in Children: Early iden-logical examinations (for example, once a year) are nec-
tification of frequent relapsers among children with minimalessary because longer CsA administration increases the
change nephrotic syndrome. J Pediatr 101:514–518, 1982rate of CsA-induced tubulointerstitial lesions. 12. International Study of Kidney Disease in Children: Primary
In addition, treatment protocols to reduce the duration nephrotic syndrome in children: Clinical significance of histopatho-
logic variants of minimal change and of diffuse mesangial hypercel-of heavy proteinuria during CsA treatment should be
lularity. Kidney Int 20:765–771, 1981developed. In this study, the Sandimmune oral solution
13. Churg J, Habib R, White RHR: Pathology of the nephrotic syn-was administered and CsA blood trough levels were used
drome. A report for the International Study of Kidney Disease in
to monitor the drug concentration. However, the trough Children. Lancet 1:1299–1302, 1970
levels do not necessarily reflect the area under the con- 14. Feutren G, Mihatch MJ: Risk factors for cyclosporine-induced
nephropathy in patients with antoimmune diseases. N Engl J Medcentration-time curve. Neoral (Novartis Pharma K.K.,
326:1654–1660, 1992Tokyo, Japan), a CsA microemulsion, has been devel-
15. Niaudet P, Broyer M, Habib R: Treatment of idiopathic nephroticoped recently. A single blood concentration measure- syndrome with cyclosporin A in children. Clin Nephrol 35(Suppl):
ment two hours after Neoral administration (C2) in both S31–S36, 1991
liver and kidney transplant recipients was shown to be 16. Habib R, Niaudet P: Comparison between pre- and posttreatment
renal biopsies in children receiving ciclosporine for idiopathic ne-a significantly more accurate predictor of drug exposure
phrosis. Clin Nephrol 42:141–146, 1994than trough concentrations, and its use resulted in a
17. Ponticelli C, Passerini P: Treatment of the nephrotic syndromereduction in the incidence and severity of cellular rejec- associated with primary glomerulonephritis. Kidney Int 46:595–604,
tion [19]. Therefore, it is possible that the use of Neoral 1994
18. Kikuchi H, Kawachi H, Ito Y, et al: Severe proteinuria, sustainedand C2 monitoring may be an efficient strategy to reduce
for 6 months, induces tubular epithelial cell injury and cell infiltra-the duration of heavy proteinuria during CsA treatment.
tion in rats but not progressive interstitial fibrosis. Nephrol Dial
Transplant 15:799–810, 2000
ACKNOWLEDGMENTS 19. Levy GA: C2 monitoring strategy for optimising cyclosporin immu-
nosuppression from the Neoral formulation. BioDrugs 15:279–290,The authors thank Drs. A. Kameda, K. Kitagawa, H. Minami, and
2001Y. Inoue for their support in collecting data.
